Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers
Open Access
- 1 January 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 1 (1), 001-010
- https://doi.org/10.29328/journal.apmh.1001001
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisCMAJ : Canadian Medical Association Journal, 2011
- Tobacco craving in smokers with and without schizophreniaSchizophrenia Research, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Herpes zoster ophthalmicus and the risk of strokeNeurology, 2010
- Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and TherapeuticsAnnual Review of Pharmacology and Toxicology, 2009
- A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in SchizophreniaBiological Psychiatry, 2008
- Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart reviewSchizophrenia Research, 2008
- Genetics of Smoking and SchizophreniaJournal of Dual Diagnosis, 2007
- Approach to Treatment of the Patient with Metabolic Syndrome: Lifestyle TherapyThe American Journal of Cardiology, 2005
- A Longitudinal Study of Premorbid IQ Score and Risk of Developing Schizophrenia,Bipolar Disorder, Severe Depression, and Other Nonaffective PsychosesArchives of General Psychiatry, 2004